News Archive

Levels of nine blood proteins can accurately predict high or low risk of serious cardiovascular events

A study published online today in the Journal of the American Medical Association (JAMA) details the first successful effort to measure at scale the levels of more than a thousand proteins in blood in patients with coronary heart disease, and describes the identification of a combination of nine specific proteins whose levels taken together can accurately predict the risk of future heart attacks, strokes, heart failure or death.

read more

Matthew (“Matt”) Norkunas, M.D., announced as new SomaLogic CFO

SomaLogic, Inc. announced today that Matthew Norkunas, M.D. has joined the company as Chief Financial Officer (CFO). Prior to SomaLogic, Dr. Norkunas was a Senior Research Analyst at Marsico Capital Management in Denver focused on biotech, pharma, life sciences, and diagnostics companies.

read more

SomaLogic completes agreement with Bristol-Myers Squibb for expanded access to SOMAmer reagents

SomaLogic, Inc. announced today that it signed an agreement with the Bristol-Myers Squibb Company (NYSE-BMY) to provide expanded access to its proprietary SOMAmer reagents. The agreement covers both the 1,310 reagents available in the current public version of the SOMAscan assay, as well as custom SOMAmer reagents developed through SomaLogic’s SOMAmer Discovery Service specifically for Bristol-Myers Squibb.

read more

SomaLogic and Otsuka scientists publish paper describing therapeutic potential of novel SOMAmer reagent for rheumatoid arthritis

In a “Fast Track” article published in the journal Nucleic Acid Therapeutics, researchers from SomaLogic and Otsuka Pharmaceutical describe a series of studies that demonstrate that treatment with a novel Slow Off-rate Modified Aptamer (SOMAmer) molecule can significantly delay the onset and reduce the severity of rheumatoid arthritis in a cynomolgus monkey model of the disease.

read more